Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Boulware, MD, MPH
University of Minnesota
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alberta
Edmonton, Alberta, Canada
- University of Manitoba
Winnipeg, Manitoba, Canada
- Research Institute of the Mcgill University Heath Centre
Montreal, Quebec, Canada
- Nationwide Enrollment Via Internet, Please Email: Covid19@umn.Edu
Minneapolis, Minnesota, United States
- University of Minnesota
Minneapolis, Minnesota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 17 Mar 2020
- Primary completion
- 20 May 2020
- Completion
- 20 May 2020
- Last update posted
- 13 May 2021
- Registered enrollment
- 1,312
- Registry id
- NCT04308668
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.